ArticleInternational journal of surgery case reports2025
Tall cell carcinoma with reverse polarity of the breast in a young patient: A case report.
Article in International journal of surgery case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tall Cell Carcinoma of the Breast With Reverse Polarity: Expanding the Molecular Spectrum WithClinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and importanceTall cell carcinoma with reverse polarity (TCCRP) is a rare and newly recognized subtype of invasive breast carcinoma, first described in 2003. It shares histological similarities with tall cell papillary thyroid carcinoma, characterized by papillary structures with reverse cellular polarity. Due to its rarity, TCCRP has been poorly understood, and fewer than 100 cases have been reported globally. This report presents the first case of TCCRP in South Tunisia, contributing to the growing body of knowledge regarding this rare tumor. CASE PRESENTATION: A 34-year-old woman with no significant personal or family history of breast cancer presented with an incidental finding of a 1 cm breast mass. Imaging studies revealed an atypical mass classified as ACR 4a. Histological analysis following lumpectomy showed circumscribed nests of epithelial cells with delicate fibrovascular cores, resembling papillary structures. Immunohistochemical staining revealed diffuse positivity for cytokeratin 5/6 and calretinin, and negativity for estrogen, progesterone, HER-2, and TTF1. The diagnosis of TCCRP was confirmed. The tumor was classified as SBR grade I, with no lymphovascular invasion or carcinoma in situ. No metastasis was observed in the 31 axillary lymph nodes. CLINICAL DISCUSSION: TCCRP primarily affects women over 60, with a low incidence in younger individuals. It typically presents as a small, palpable breast mass. Histologically, TCCRP exhibits a solid-papillary architecture with tall cells, reverse polarity, and rare foamy histiocytes. Immunohistochemical findings include negative estrogen, progesterone, HER-2, and TTF1 markers, along with positive staining for calretinin. Molecular studies have revealed IDH2 and PIK3CA mutations in the majority of cases. Despite being triple-negative, TCCRP has a favorable prognosis, with low rates of metastasis or recurrence.
conclusionTCCRP is a rare subtype of invasive breast carcinoma with distinct histological and immunohistochemical features. It is characterized by an indolent clinical course and an excellent prognosis. Conservative surgical management with clear margins is the optimal treatment approach, with no clear indications for lymph node dissection, chemotherapy, or radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.